



US008778346B2

(12) **United States Patent**  
**Barrett et al.**(10) **Patent No.:** **US 8,778,346 B2**  
(45) **Date of Patent:** **Jul. 15, 2014**(54) **ANTI-IL-23 ANTIBODIES**(75) Inventors: **Rachel Rebecca Barrett**, Bethel, CT (US); **Keith Canada**, Southbury, CT (US); **Katrina Mary Catron**, Middlebury, CT (US); **Robert Copenhaver**, Portland, OR (US); **Lee Edward Frego**, Hopewell Junction, NY (US); **Ernest Lee Raymond**, New Milford, CT (US); **Sanjaya Singh**, Sandy Hook, CT (US); **Xiangyang Zhu**, Ridgefield, CT (US)(73) Assignee: **Boehringer Ingelheim International GmbH**, Ingelheim am Rhein (DE)

( \* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/287,208**(22) Filed: **Nov. 2, 2011**(65) **Prior Publication Data**

US 2012/0282269 A1 Nov. 8, 2012

**Related U.S. Application Data**

(60) Provisional application No. 61/448,785, filed on Mar. 3, 2011, provisional application No. 61/412,594, filed on Nov. 11, 2010, provisional application No. 61/411,953, filed on Nov. 10, 2010, provisional application No. 61/410,158, filed on Nov. 4, 2010.

(51) **Int. Cl.****A61K 39/395** (2006.01)  
**C07K 16/46** (2006.01)  
**C07K 16/24** (2006.01)  
**A61K 39/00** (2006.01)(52) **U.S. Cl.**CPC ..... **C07K 16/244** (2013.01); **C07K 231/24** (2013.01); **C07K 231/76** (2013.01); **A61K 2039/505** (2013.01); **C07K 231/92** (2013.01); **C07K 231/34** (2013.01)  
USPC ..... **424/158.1**; 530/387.9; 530/388.23; 530/389.2; 536/23.53(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited****U.S. PATENT DOCUMENTS**6,060,284 A 5/2000 Bazan  
6,479,634 B1 11/2002 Bazan  
6,495,667 B1 12/2002 Bazan  
6,610,285 B1 8/2003 Hirata  
6,756,481 B2 6/2004 Chirica et al.  
6,835,825 B1 12/2004 Bazan  
7,090,847 B1 8/2006 Oppmann et al.  
7,183,382 B2 2/2007 Oppmann et al.  
7,252,967 B2 8/2007 Hirata  
7,282,204 B2 10/2007 Oft et al.  
7,332,156 B2 2/2008 Bowman et al.7,411,041 B2 8/2008 Chirica et al.  
7,422,743 B2 9/2008 Chirica et al.  
7,427,402 B2 9/2008 Kastelein et al.  
7,491,391 B2 2/2009 Benson et al.  
7,501,247 B2 3/2009 Kastelein et al.  
7,510,709 B2 3/2009 Gurney  
7,510,853 B2 3/2009 Chirica et al.  
7,575,741 B2 8/2009 Bowman et al.  
7,608,690 B2 10/2009 Bazan  
7,740,848 B2 6/2010 Kastelein et al.  
7,749,718 B2 7/2010 Chirica et al.  
7,750,126 B2 7/2010 Hirata  
7,754,214 B2 7/2010 Chirica et al.  
7,790,862 B2 9/2010 Lewis et al.  
7,807,160 B2 10/2010 Presta et al.  
7,807,414 B2 10/2010 Benson et al.  
7,820,168 B2 10/2010 Cua et al.  
7,872,102 B2 1/2011 Beidler et al.  
7,883,695 B2 2/2011 Oppmann et al.  
7,887,806 B2 2/2011 Chirica et al.  
7,893,215 B2 2/2011 Bowman et al.  
7,910,703 B2 3/2011 Lewis et al.  
7,935,344 B2 5/2011 Benson et al.  
7,993,645 B2 8/2011 Benson et al.  
8,106,177 B2 1/2012 Benson et al.  
2004/0219150 A1 11/2004 Cua et al.  
2004/0258686 A1 12/2004 Chirica et al.  
2005/0039222 A1 2/2005 Habu et al.  
2005/0100917 A1 5/2005 Chirica et al.  
2005/0100918 A1 5/2005 Chirica et al.  
2005/0208052 A1 9/2005 Katsikis et al.  
2005/0244874 A1 11/2005 Kastelein et al.  
2005/0287593 A1 12/2005 Kastelein et al.  
2006/0140958 A1 6/2006 Hogan et al.  
2007/0009526 A1 1/2007 Benson et al.

(Continued)

**FOREIGN PATENT DOCUMENTS**EP 1072610 A1 1/2001  
WO 9905280 A1 2/1999

(Continued)

**OTHER PUBLICATIONS**Alegre, Maria-Luisa et al. "A Non-Activating "Humanized" Anti-CD3 Monoclonal Antibody Retains Immunosuppressive Properties in Vivo" Transplantation; Jun. 1994, vol. 57, No. 11, pp. 1537-1543.  
Beyer, Brian M. et al. "Crystal Structures of the Pro-Inflammatory Cytokine Interleukin-23 and its Complex with a High-Affinity Neutralizing Antibody" Journal of Molecular Biology, (2008) 382, pp. 942-955.

Chan, Andrew C. et al. "Therapeutic antibodies for autoimmunity and inflammation" Nature Reviews, Immunology, May 2010, vol. 10, pp. 301-316.

International Search Report &amp; Written Opinion for PCT/US2011/058869 filed Nov. 2, 2011, mailed Feb. 27, 2012.

(Continued)

*Primary Examiner* — Bridget E Bunner*Assistant Examiner* — Fozia Hamud(74) *Attorney, Agent, or Firm* — Michael P. Morris; Edouard G. Lebel(57) **ABSTRACT**

The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.

**46 Claims, 3 Drawing Sheets**